Search Results - ovarian+cancer

5 Results

Sort By:

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Summary: The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies. Description of Technology: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li

Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Metastatic ovarian cancer mouse models and cell lines for preclinical studies

Abstract: The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs at a high rate. One of the rate limiting factors...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Simone Difilippantonio, Terry Van Dyke, Ludmila Szabova, Chaoying Yin, Yurong Song

Keywords(s): GDA, GEM Derived Allograft Mouse Model, Genetically Engineered Mouse (GEM) Model, OVARIAN CANCER, SEOC, Serous Epithelial Ovarian Cancer

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials

Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines

Description of Technology: Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Stuart Aaronson, Nelson Ellmore (Estate)

Keywords(s): A2780, Aaronson, adriamycin, CISPLATIN, drug resistance, IRRADIATION, Melphalan, OVARIAN CANCER, VINBLASTINE

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials

Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES

Summary: NCI is seeking parties to non-exclusively license the ADR-RES cell line. Description of Technology: Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Kenneth Cowan

Keywords(s): ADENOCARCINOMA, Adriamycin-resistant, Cell line, Cowan, MCF-7/ADR-RES, MDR1, Multi-Drug Resistance, NCI/ADR-RES, OVARIAN CANCER, OVCAR-8, P-GLYCOPROTEIN

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Oncology

Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN

PTEN is a tumor suppressor gene that is frequently deleted or mutated in a variety of human cancers, including prostate, breast, endometrial, lung, and ovarian cancers. In prostate cancer cells, PTEN deletion is the most common event observed. The loss of PTEN is thought to play and important role in tumor cell proliferation and metastasis due to...

Published: 5/7/2025 | Updated: 12/6/2022 | Inventor(s): Michael Quon, Derek Leroith

Keywords(s): ADENOCARCINOMA, BREAST CANCER, CA1XXX, CANCER, CAXXXX, CCXXXX, Cells, CHARACTERIZATION, Chromosome 7, monosomy, CXXXXX, Deletion 7, endometrial, Expressing, Gene, IGF1R, lung cancer, MEN 1, OVARIAN CANCER, PROSTATE CANCER, PTEN, tumor suppressor, Zollinger-Ellison syndrome

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials